Collegium Pharmaceutical (COLL) Revenue (2016 - 2026)

Collegium Pharmaceutical's Revenue history runs 11 years deep, the most recent figure standing at $193.5 million for Q1 2026.

• On a quarterly basis, Revenue rose 8.87% year-over-year to $193.5 million in Q1 2026; TTM through Mar 2026 was $796.3 million, a 53.27% increase from a year earlier, with the FY2025 full-year figure at $780.6 million, up 23.62% from the prior year.
• Revenue declined to $193.5 million in Q1 2026 per COLL's latest filing, from $205.4 million in the prior quarter.
• Across five years, Revenue topped out at $209.4 million in Q3 2025 and bottomed at $37.2 million in Q4 2024.
• The 5-year median for Revenue is $144.9 million (2024), against an average of $147.2 million.
• Across the five-year window, Revenue sank 75.13% in 2024 and soared 451.7% in 2025, its largest moves.
• Year by year, Revenue stood at $140.7 million in 2022, then rose by 6.46% to $149.7 million in 2023, then sank by 75.13% to $37.2 million in 2024, then surged by 451.7% to $205.4 million in 2025, then dropped by 5.81% to $193.5 million in 2026.
• Per Business Quant, the three latest COLL Revenue figures stand at $193.5 million (Q1 2026), $205.4 million (Q4 2025), and $209.4 million (Q3 2025).